Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response
Biomolecules · 2023
DOI: 10.3390/biom14010001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von María Angels Ortiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Ba…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Farma S.A., Institut Recerca Hospital de la Santa Creu i Sant Pau, Roche.
Abstract (Originalsprache)
In rheumatoid arthritis (RA) synovium, ATP, and ADP are released, sparking inflammation. Ectoenzymes CD39 and CD73 metabolize these purine nucleotides, generating anti-inflammatory adenosine. Therefore, dysregulated CD39 and CD73 expression may impact RA development. We assessed CD39 and CD73 expression in peripheral blood from 15 healthy controls (Cs) and 35 RA patients at baseline and after 3 and 6 months of tocilizumab treatment using flow cytometry. Additionally, ectoenzyme expression was examined on cultured T cells to understand activation and IL-6 effects. At baseline, RA patients exhibited a lower CD8+CD39−CD73+ cell percentage, which inversely correlated with DAS28. Additionally, they had lower percentages of Treg CD39+CD73+ and CD39−CD73− cells. Good responders tended to have lower B CD39+CD73+ cell percentages at baseline and 3 months. Additionally, Treg, CD8+ T and B cells inversely correlated with DAS28. T-cell activation increased CD39 and decreased CD73 expression, regardless of IL-6. IL-6 reduced IFNγ-secreting CD4+ T-cell percentage in Cs, but increased the percentage of IFNγ-secreting CD4+ and CD8+ T cells in RA patients. These findings indicate differing CD39 and CD73 expression in RA and Cs, influenced by T-cell activation and IL-6. Correlations between these molecules and RA activity suggest their role in dysregulated inflammation in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
- Rheumatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
- Rheumatology Department, Hospital Vall d'Hebrón, 08035 Barcelona, Spain.
- Rheumatology Department, Hospital Moisès Broggi, Sant Joan Despí, 08970 Barcelona, Spain.
- Rheumatology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
- Department of Rheumatology, Universitat Autònoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Spain.
ORCID-Profile: María Angels Ortiz, Cesar Diaz-Torné, Hector Corominas, Silvia Vidal
Förderung
- Roche Farma S.A.
- Institut Recerca Hospital de la Santa Creu i Sant Pau
- Roche
Zitieren
APA
Ortiz, M. A., Diaz-Torné, C., De Agustin, J. J., Estrada, P., Reina, D., Hernandez, M. V., Sang, H., Zamora, C., Cantó, E., Corominas, H., & Vidal, S. (2023). Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules. https://doi.org/10.3390/biom14010001
Vancouver
Ortiz MA, Diaz-Torné C, De Agustin JJ, Estrada P, Reina D, Hernandez MV, et al. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules. 2023. doi:10.3390/biom14010001
BibTeX
@article{Ortiz2023,
author = {Ortiz, María Angels and Diaz-Torné, Cesar and De Agustin, Juan Jose and Estrada, Paula and Reina, Delia and Hernandez, María Victoria and Sang, Hye and Zamora, Carlos and Cantó, Elisabet and Corominas, Hector and Vidal, Silvia},
title = {Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom14010001}
}
EUVIMED